S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
NASDAQ:LIAN

LianBio (LIAN) Stock Price, News & Analysis

$0.31
-0.02 (-6.13%)
(As of 03/27/2024 ET)
Today's Range
$0.31
$0.35
50-Day Range
$0.31
$4.99
52-Week Range
$0.27
$4.99
Volume
78,192 shs
Average Volume
1.04 million shs
Market Capitalization
$33.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.33

LianBio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,642.1% Upside
$5.33 Price Target
Short Interest
Healthy
0.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.08mentions of LianBio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $2.40 to ($0.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.87 out of 5 stars

Medical Sector

436th out of 938 stocks

Biotechnology Industry

10th out of 24 stocks

LIAN stock logo

About LianBio Stock (NASDAQ:LIAN)

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LIAN Stock Price History

LIAN Stock News Headlines

Why Is LianBio (LIAN) Stock Moving Today?
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
LianBio Announces Voluntarily Delisting from Nasdaq
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
LianBio Announces Completion of Strategic Review
B of A Securities Downgrades LianBio: Here's What You Need To Know
Interest Is Growing for Smaller, More Speculative Names
LianBio Announces Departure of Chief Financial Officer
LianBio Names Stone as Interim CEO as Wang Resigns
LianBio Announces Departure of Chief Executive Officer
See More Headlines
Receive LIAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LianBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2023
Dividend Payable
3/14/2024
Ex-Dividend for 3/14 Dividend
3/15/2024
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:LIAN
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.33
High Stock Price Target
$9.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+1,642.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-110,290,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.71 per share

Miscellaneous

Free Float
99,861,000
Market Cap
$33.08 million
Optionable
Not Optionable
Beta
0.23
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Konstantin Poukalov (Age 40)
    Founder & Executive Chairman
  • Mr. Adam Leo Stone (Age 43)
    Interim CEO & Director
  • Ms. Ehong Gu
    Interim CFO, VP & Head of Global Finance
  • Ji Chen
    Senior VP & General Counsel
  • Ms. Brianne Jahn (Age 38)
    Chief Business Officer
    Comp: $697.47k
  • Dr. Michael Humphries M.D.
    Chief Scientific Advisor
  • Mr. Levvy Lv D. Eng
    Senior VP & Global Head of Development

LIAN Stock Analysis - Frequently Asked Questions

Should I buy or sell LianBio stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LianBio in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" LIAN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIAN, but not buy additional shares or sell existing shares.
View LIAN analyst ratings
or view top-rated stocks.

What is LianBio's stock price target for 2024?

3 brokers have issued 12-month price objectives for LianBio's stock. Their LIAN share price targets range from $3.00 to $9.00. On average, they expect the company's stock price to reach $5.33 in the next year. This suggests a possible upside of 1,642.1% from the stock's current price.
View analysts price targets for LIAN
or view top-rated stocks among Wall Street analysts.

How have LIAN shares performed in 2024?

LianBio's stock was trading at $4.47 at the start of the year. Since then, LIAN shares have decreased by 93.2% and is now trading at $0.3062.
View the best growth stocks for 2024 here
.

How were LianBio's earnings last quarter?

LianBio (NASDAQ:LIAN) released its quarterly earnings results on Monday, March, 27th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.10.

How often does LianBio pay dividends? What is the dividend yield for LianBio?

LianBio declared a -- dividend on Tuesday, February 13th. Stockholders of record on Tuesday, February 27th will be paid a dividend of $4.80 per share on Thursday, March 14th. The ex-dividend date is Friday, March 15th.
Read our dividend analysis for LIAN
.

What ETF holds LianBio's stock?

Loncar China Biopharma ETF holds 27,778 shares of LIAN stock, representing 1.31% of its portfolio.

When did LianBio IPO?

LianBio (LIAN) raised $325 million in an initial public offering on the week of November 1st 2021. The company issued 20,300,000 shares at $16.00 per share. Goldman Sachs, Jefferies and BofA Securities served as the underwriters for the IPO.

Who are LianBio's major shareholders?

LianBio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Affinity Asset Advisors LLC (3.50%), Axxcess Wealth Management LLC (0.03%) and Donald L. Hagan LLC (0.02%).
View institutional ownership trends
.

How do I buy shares of LianBio?

Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIAN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners